目的：观察玻璃体腔注射康柏西普对不同OCT分型糖尿病黄斑水肿(DME)的疗效差异。

方法：DME患者96例96眼根据OCT形态特征将DME分为弥漫性黄斑水肿(DRT，35眼)、囊性黄斑水肿(CME，33眼)、浆液性视网膜脱离(SRD，28眼)，所有患者行玻璃体腔注射0.5mg(0.05mL)康柏西普治疗。治疗后1、3、6mo，比较三组BCVA(LogMAR)、黄斑中心凹视网膜厚度(CFT)、注射次数及视力提高眼数的差异。

结果：随访6mo，三组患眼BCVA呈明显下降趋势(F_时间=205.880，P_时间<0.01)，三组间比较有差异(F_组间=3.472，P_组间=0.042)，其中DRT组治疗后BCVA改善最佳； 三组患眼CFT呈明显降低趋势(F_时间=392.994，P_时间<0.01)，三组间比较有差异(F_组间=5.046，P_组间=0.012)，DRT组和CME组的CFT降低程度优于SRD组。随访6mo DRT组的注射次数最少，视力提高眼数比例最高。

结论：玻璃体腔注射康柏西普可显著改善不同OCT分型DME患眼的视力，降低CFT，其中DRT疗效最佳，注射次数最少。

METHODS: A total of 96 patients(96 eyes)with DME were classified as diffuse retinal thickening(DRT group, 35 eyes), cystoid macular edema(CME group, 33 eyes)and serous retinal detachment(SRD group, 28 eyes)according to the OCT. All patients were treated with intravitreal injection of 0.5mg(0.05mL)conbercept. The changes of best corrected visual acuity(BCVA), central foveal thickness(CFT), the injection times and vision improves eyes were compared between three groups after 1,3,6mo treatment.

RESULTS: After 6mo follow up, the BCVA of the three groups showed a significant downward trend(F_time=205.880, P_time<0.01), and there were significant differences among the three groups(F_group=3.472, P_group=0.042). The DRT group had the best BCVA after treatment. The CFT of the three groups showed a significant downward trend(F_time=392.994, P_time<0.01), and there were significant differences among the three groups(F_group=5.046, P_group=0.012). The reduction of CFT in the DRT group and CME group were better than that in the SRD group. The DRT group had the least injection times, and the highest proportion of vision improves eyes after 6mo follow up.

CONCLUSION: The intravitreal injection of conbercept could significantly improve the visual acuity and reduce the CFT of DME with different OCT patterns. And DRT is the most effective type with the least injection times.